MagnetisMM-30: Elranatamab + iberdomide for RRMM

Results from Part 1 (dose escalation) of the phase Ib, open-label, multicenter MagnetisMM‑30 trial (NCT06215118), evaluating elranatamab (Elra) in combination with iberdomide (Iber), were presented by Attaya Suvannasankha at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US. The study enrolled 22 patients with relapsed/refractory multiple myeloma (RRMM) and 2–4 prior lines of therapy (LoT). Preliminary data were reported for dose level (DL) 1 (Elra 76 mg weekly plus Iber 1.0 mg once daily [QD]) and DL−1 (Elra 76 mg every 2 weeks plus Iber 1.0 mg QD). The primary endpoint was the incidence of dose-limiting toxicities (DLTs).

Key data: The safety profile of the combination was consistent with the known profiles of the individual agents. Median relative dose intensity (RDI) across dose levels was 78.2% for Elra and 74.3% for Iber. The RDI for Elra was lower in DL1 compared with DL−1 (73.6% vs 86.9%), whereas the RDI for Iber was comparable between DL1 and DL−1 (74.3% vs 74.3%). Dose interruptions occurred in 81.8% of patients for both Elra and Iber across dose levels. No dose reductions were reported with Elra, whereas dose reductions occurred in 54.5% of patients receiving Iber across both dose levels. At a median follow-up of 7.8 months, the overall response rate (ORR) in the overall cohort was 95.5% (95% confidence interval [CI], 77.2–99.9), including an ORR of 92.3% (95% CI, 64.0–99.8) in the DL1 cohort and 100.0% (95% CI, 66.4–100.0) in the DL−1 cohort.

Key learning: The combination of Elra plus Iber demonstrated a safety profile consistent with the known profiles of the individual agents, with further evaluation of the two dosing schedules ongoing in Part 2 (dose expansion) of the trial.